TG Therapeutics publishes five-year Briumvi comparison study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. MSFT
3. PLTR
4. SPY
5. KTOS
6. AON
7. TMUS
8. LBRX
9. BMY
10. MRK

Go back to TG Therapeutics publishes five-year Briumvi comparison study

TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis

October 12, 2026 7:30 AM EDT

BRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab

NEW YORK--(BUSINESS WIRE)-- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression outcomes with BRIUMVI® (ublituximab-xiiy) compared with ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). For the analysis, individual patient data from the Phase 3 ULTIMATE I/II pivotal trials for BRIUMVI were reweighted to match published... More